Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability Study of ANK-700 in Relapsing Remitting Multiple Sclerosis
NCT04602390Phase 1Completed
- Sponsor
- Anokion
- Start
- Nov 2020
- Primary completion
- Apr 2024
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ANK-700 in relapsing-remitting multiple sclerosis (RRMS) (5 cohorts), sponsored by Anokion. Primary endpoint: Treatment-emergent Adverse Events up to 1 year. Started Nov 2020; status: completed.
02
Drugs
ANK-700
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT04602390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04602390.